Alkermes (ALKS)
(Delayed Data from NSDQ)
$26.59 USD
-0.52 (-1.92%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.59 USD
-0.52 (-1.92%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
Alkermes (ALKS) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 216.67% and 5.22%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
Alkermes Boasts Strong Portfolio and Impressive Pipeline
by Zacks Equity Research
Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.
EBS or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EBS vs. ALKS: Which Stock Is the Better Value Option?
FDA Sets Action Date for Recro's Pain Management Candidate
by Zacks Equity Research
The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.
VistaGen Up on Fast Track Designation to Pain Candidate
by Zacks Equity Research
VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.
Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA
by Zacks Equity Research
FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.
Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo
by Zacks Equity Research
Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.
ANIK vs. ALKS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ANIK vs. ALKS: Which Stock Is the Better Value Option?
What's in Store for Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.
What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.
Is a Beat in the Cards for Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 earnings is likely to gain from higher membership and revenues from Government business.
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
by Zacks Equity Research
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
Company News For Jul 3, 2018
by Zacks Equity Research
Companies in the news are: CLB, ALKS, ACXM and URI
Key FDA Events in June Investors Need to Watch Out For
by Zacks Equity Research
Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.
The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes
4 Top Stocks to Buy As Irish Economy Gathers Steam
by Nitish Marwah
EU remains upbeat about growth prospects of the Irish economy in the years to come.
Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
by Zacks Equity Research
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Alkermes Rallies as FDA Accepts NDA for Depression Drug
by Zacks Equity Research
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Company News For Apr 17, 2018
by Zacks Equity Research
Companies In The News are: JBHT,ERI,MRK,ALKS